New hope for breast cancer patients: An FDA panel has backed a pre-surgery drug that doctors say could help women fight breast cancer earlier — and live longer cancer-free. Full FDA approval could come as early as next month. NBC’s John Yang reports.
Visit NBCNews.com for breaking news, world news, and news about the economy
Perjeta won the backing of U.S. regulatory advisers to potentially become the first pre-surgical drug treatment for breast cancer that could lead to a less-invasive procedure.
The benefits of expanding use of Perjeta to early-stage breast cancer patients outweigh the risks, advisers to the Food and Drug Administration voted 13-0 today in Silver Spring, Maryland. The drug was approved last year for patients with HER2-positive advanced breast cancer that has spread.